Attenuated anti-SARS-CoV-2 antibody response to vaccination in patients with rheumatic diseases.

Manolache, Narcis-George;Ursachi, Vasile;Scohy, Anaïs;Desmet, Charlotte;Stoenoiu, Maria Simona;et.al.
(2022) Journal of Infection — Vol. 84, n° 2, p. e22-e23 (2022)

Files

main.pdf
  • Open Access
  • Adobe PDF
  • 483.8 KB
Download

Details

Authors
Show more
Abstract
(en) Dear Editor, SARS-CoV-2 vaccination has demonstrated efficacy in large clin- ical trials but immunocompromised patients including patients with rheumatic diseases are often excluded. A recent letter in Jour- nal of Infection identified an anti-receptor binding domain (RBD) antibody (Ab) threshold below which protection against SARS-CoV- 2 infection is inferior to 90% [ ... ].
Affiliations

Citations

  • APA
  • Chicago
  • FWB

Manolache, N.-G., Ursachi, V., Scohy, A., Desmet, C., Yombi, J. C., Nzeusseu Toukap, A., & Stoenoiu, M. S. (2022). Attenuated anti-SARS-CoV-2 antibody response to vaccination in patients with rheumatic diseases. Journal of Infection, 84(2), e22-e23. https://doi.org/10.1016/j.jinf.2021.12.006 (Original work published 2022)